J. Schippers

Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial

W. Boersma, E. Nossent, J. Geelhoed, 2021, The Lancet Respiratory Medicine.

Immunomodulation and endothelial barrier protection mediate the association between oral imatinib and mortality in hospitalised COVID-19 patients

T. van der Poll, H. Peters-Sengers, J. Duitman, 2022, The European respiratory journal.

Immunomodulation and endothelial barrier protection mediate the association between oral imatinib and mortality in hospitalised COVID-19 patients

T. van der Poll, H. Peters-Sengers, J. Duitman, 2022, European Respiratory Journal.

The INVENT COVID trial: a structured protocol for a randomized controlled trial investigating the efficacy and safety of intravenous imatinib mesylate (Impentri®) in subjects with acute respiratory distress syndrome induced by COVID-19

D. Cavalla, P. Tuinman, L. Heunks, 2022, Trials.

Long-term clinical outcomes of COVID-19 patients treated with imatinib

J. Twisk, A. Noordegraaf, H. Bogaard, 2022, The Lancet Respiratory Medicine.

Cardiac Safety of Imatinib for the Treatment of COVID-19: A Secondary Analysis of a Randomized, Double-Blind, Placebo-Controlled Trial

F. D. de Man, H. Bogaard, E. Duijvelaar, 2022, Journal of cardiovascular pharmacology.

Pharmacokinetics and pharmacodynamics of imatinib for optimal drug repurposing from cancer to COVID-19

J. Twisk, E. Swart, S. Fritchley, 2023, European Journal of Pharmaceutical Sciences.

Efficacy and safety of intravenous imatinib in COVID-19 ARDS: a randomized, double-blind, placebo-controlled clinical trial

D. Cavalla, H. Endeman, P. Tuinman, 2023, Critical Care.